Railroad played major part in Sheldon growth
SHELDON, Iowa (KCAU) —Sheldon was founded in 1872, coinciding with the arrival of the Sioux City and St. Paul — now Union Pacific — Railway.
The town was named after Israel Sheldon, a stockholder in the railroad. Though Isreal Sheldon never lived in Sheldon, growth was immediate.
The community sits at the intersection of two major highways, Highways 18 and 60, making it easy to get to. But it was the railroad that played major part in town's growth.
'[Israel Sheldon] was a big deal in New York. He was in the railroad industry. He had lots of things he was into, but the railrolad was a big deal,' local historian Millie Voss told KCAU 9.
Sheldon community continues to see growth
'Sheldon was a commercial hub. eighteen trains came through Sheldon a day. We even had a train that took people to Sioux City to go shopping and return the same day,' historian Tom Whorley said.
Sheldon's first industry, Prairie Queen Flour Mill, played a part in the growth. It was built in 1879. It would process 150 to 200 barrels of flour every 24 hours and required 25 to 30 employees. The mill's monthly payroll was about $2,000.
For more of KCAU 9's Hometown Proud stories, CLICK HERE.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
Aeluma Inc trading resumes
13:06 EDT Aeluma (ALMU) Inc trading resumes Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Yahoo
an hour ago
- Yahoo
Rakuten Medical Selected to Participate in FDA CEO Forum in San Diego
- Engaged with FDA Commissioner on shared commitment to fast, safe, and affordable patient access to innovative therapies SAN DIEGO, June 13, 2025 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, today announced that it was selected by the U.S. Food and Drug Administration (FDA) to participate in the FDA CEO Forum in San Diego, California, on June 13, 2025. Minami Maeda, President of Rakuten Medical, attended the meeting in person as a member of this panel, to discuss with FDA Commissioner Marty A. Makary, M.D., M.P.H., and other industry leaders how the FDA can "modernize its regulatory framework to better support innovation and patient access to safe and effective therapies". Rakuten Medical – whose innovative cancer therapeutic technology, the Alluminox™ platform, is in Phase 3 trials in the U. S. – was selected to join the forum as one of the companies at the front lines of medical discovery. Rakuten Medical's novel treatment modality, known as photoimmunotherapy, is designed to induce rapid and selective depletion of cancer or immunosuppressive cells with minimal impact on surrounding healthy tissue. Moreover, pre-clinical observation have shown that photoimmunotherapy may also stimulate both innate and adaptive anti-tumor immune responses. "Rakuten Medical's Alluminox™ platform has the potential to transform cancer therapy in the U.S.," said Maeda. "We are honored to be recognized by the FDA and invited to contribute to discussions on how regulatory innovation can accelerate the delivery of pioneering treatments to patients. We fully support the FDA's vision of a modern framework that ensures timely access, safety, and affordability." Rakuten Medical is currently conducting a global Phase 3 clinical trial evaluating its ASP-1929 photoimmunotherapy in combination with pembrolizumab as a first-line treatment for patients with recurrent head and neck squamous cell carcinoma (HNSCC) (Protocol number: ASP-1929-381 / Acronym: ECLIPSE / Identifier: NCT06699212). A prior Phase 1b/2 study showed promising interim evaluation results, including a 24-month survival rate of 52.4% and a median overall survival (OS) not yet reached. ASP-1929 photoimmunotherapy received the world's first regulatory approval in Japan under the Conditional Early Approval System based on a certain level of efficacy and acceptable safety from Phase 1/2a trial results. It is being delivered to patients in Japan at an affordable price. Disclaimer: Rakuten Medical's Alluminox™ platform-based photoimmunotherapy is investigational outside Japan. About Rakuten Medical, Inc. Rakuten Medical, Inc. is a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, which, in pre-clinical studies, has been shown to induce rapid and selective cell killing. Rakuten Medical's photoimmunotherapy is currently investigational outside Japan. Rakuten Medical is committed to its mission to conquer cancer by developing its pioneering treatments as quickly as possible to as many patients as possible all over the world. The company has offices in 5 countries/regions, including the United States, where it is headquartered, Japan, Taiwan, Switzerland and India. For more information, visit About Alluminox™ platform The Alluminox™ platform is Rakuten Medical's investigational technology platform that combines pharmaceuticals, medical devices, medical technology, and other peripheral technologies. Rakuten Medical is developing Alluminox platform-based photoimmunotherapy, which involves two key steps: 1) drug administration and 2) targeted illumination using medical devices. The drug component consists of a cell-targeting moiety conjugated to a light-activatable dye, such as IRDye® 700DX (IR700), that selectively binds to the surface of targeted cells, such as tumor cells. The device component consists of a light source that locally illuminates the targeted cells with red light (690nm) to transiently activate the drug. Rakuten Medical's pre-clinical data have shown that this activation elicits rapid and selective necrosis of targeted cells through a biophysical process that compromises the membrane integrity of the targeted cells. Therapies developed on the Alluminox platform may also result in local and systemic innate and adaptive immune activation due to immunogenic cell death of the targeted tumor cells and/or the removal of targeted immunosuppressive cells within the tumor microenvironment. Photoimmunotherapy was originally developed by Dr. Hisataka Kobayashi and his team at the National Cancer Institute in the United States. Outside Japan, Rakuten Medical's Alluminox platform-based photoimmunotherapy is investigational. About ASP-1929Rakuten Medical's first pipeline drug developed on its Alluminox™ platform is ASP-1929, an antibody-dye conjugate comprised of the anti-EGFR antibody cetuximab and IRDye® 700DX, a light activatable dye. ASP-1929 binds to epidermal growth factor receptor (EGFR), a cancer antigen expressed in multiple types of solid tumors, including head and neck, breast, lung, colorectal, prostate and pancreatic cancers. After binding to cancer cells, ASP-1929 is locally activated by illumination with red light (690 nm), emitted by a laser device system to produce a photochemical reaction. This reaction is believed to cause damage to the membrane of cancer cells, leading to selective necrosis of cancer cells. In Japan, ASP-1929 received marketing approval from the Japanese Ministry of Health, Labor, and Welfare for unresectable locally advanced or recurrent head and neck cancer in September 2020, under the Sakigake Designation System and the Conditional Early Approval System. ASP-1929 photoimmunotherapy in combination with pembrolizumab is currently under investigation in a global Phase 3 clinical trial as a first-line therapy for recurrent head and neck cancer. Outside Japan, ASP-1929 has not yet been approved for commercial use by any regulatory authority. Contact Us View original content to download multimedia: SOURCE Rakuten Medical, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Dave & Buster's Announces Promotion of Les Lehner to Chief Development Officer
DALLAS, June 13, 2025 (GLOBE NEWSWIRE) -- Dave & Buster's Entertainment, Inc., (NASDAQ: PLAY), ("Dave & Buster's" or "the Company") today announced that it has promoted Les Lehner to the position of Chief Development Officer. Mr. Lehner most recently served as Chief Procurement Officer and Head of Main Event Development. In connection with this promotion, the Company announced that John Mulleady, current Chief Development Officer, will retire effective as of the close of business on October 23, 2025. Effective as of June 30, 2025, Mr. Mulleady will transition to an advisory role at the Company to ensure a smooth transition until the effective date of his retirement. The Company and Mr. Mulleady have further agreed that he will provide consulting services to the Company from the effective date of his retirement until January 31, 2026. 'I want to express my sincere gratitude to John for his nearly 15 years of dedicated service to Dave & Buster's. During his tenure, he achieved remarkable results, leading the successful construction of over 100 new stores and consistently demonstrating best-in-class development prowess,' said Kevin Sheehan, Board Chair and Interim Chief Executive Officer. 'While John will undoubtedly be missed when he steps away in 2026, we are fortunate to be transitioning leadership of our development efforts to Les – an exceptionally capable leader within our executive team. Les has been a versatile and highly effective contributor to our organization, overseeing procurement, cost optimization, and Main Event development. I have full confidence that he will excel as our new Chief Development Officer, bringing deep industry knowledge and a proven track record of development expertise to the role. Lastly, we have an existing, well developed pipeline of approximately 40 stores we expect to open over the next three years and look forward to Les leading the Company's ongoing growth in this area.' About Les Lehner Mr. Lehner served as Chief Procurement Officer and Head of Main Event Development since August 2022. Previously he was Executive Vice President, Chief Development and Procurement Officer at Main Event Entertainment from 2018 through July 2022, and Senior Vice President, Chief Development and Procurement Officer at Red Robin Gourmet Burgers, Inc. from 2015 through 2018. Prior to that he was with CEC Entertainment from 2000 through 2015 in various roles including Senior Vice President, Development and Procurement. About Dave & Buster's Entertainment, Inc. Founded in 1982 and headquartered in Coppell, Texas, Dave & Buster's Entertainment, Inc., is the owner and operator of 236 venues in North America that offer premier entertainment and dining experiences to guests through two distinct brands: Dave & Buster's and Main Event. The Company has 175 Dave & Buster's branded stores in 43 states, Puerto Rico, and Canada and offers guests the opportunity to "Eat Drink Play and Watch," all in one location. Each store offers a full menu of entrées and appetizers, a complete selection of alcoholic and non-alcoholic beverages, and an extensive assortment of entertainment attractions centered around playing games and watching live sports and other televised events. The Company also operates 61 Main Event branded stores in 22 states across the country, and offers state-of-the-art bowling, laser tag, hundreds of arcade games and virtual reality, making it the perfect place for families to connect and make memories. For more information about each brand, visit and For Investor Relations Inquiries: Cory Hatton, Head of Entertainment Finance, Investor Relations & TreasurerDave & Buster's Entertainment, in to access your portfolio
